Cargando…

Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study

INTRODUCTION: The 1-, 3- and 6- month biodegradable polymer matrix depot formulations of leuprorelin acetate (Eligard(®)/Depo-Eligard(®), Astellas Pharma Inc/BV) were shown to reduce testosterone and prostate-specific antigen levels and to be well tolerated in patients with advanced prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braeckman, Johan, Michielsen, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2014
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107255/ https://www.ncbi.nlm.nih.gov/pubmed/25097577 http://dx.doi.org/10.5114/aoms.2014.43743

Ejemplares similares

Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer
por: de Freitas, Carla S. M., et al.
Publicado: (2020)

ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD(®)) in Asian men with prostate cancer
por: Malek, Rohan, et al.
Publicado: (2022)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn, Ulf W, et al.
Publicado: (2013)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate
por: Okada, Akie, et al.
Publicado: (2022)

Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008)

A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
por: Kim, Dohee, et al.
Publicado: (2019)

A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin
por: Park, Woo Sung, et al.
Publicado: (2014)

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls
por: Yang, Kun, et al.
Publicado: (2021)

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
por: Suzuki, Kazuhiro, et al.
Publicado: (2015)

Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer
por: Tan, Hsern Ern, et al.
Publicado: (2016)

Foreign Body Granuloma Secondary to Leuprorelin Acetate
por: Lee, Bo In, et al.
Publicado: (2014)

The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot.
por: Matalliotakis, I M, et al.
Publicado: (2001)

Conjunctival Necrosis due to Subconjunctival Methylprednisolone (Depo-Medrol™) Acetate Injection
por: van Zyl, L. M., et al.
Publicado: (2010)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Routine dipstick urinalysis in daily practice of Belgian occupational physicians
por: Braeckman, Lutgart, et al.
Publicado: (2012)

Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem
por: Ozgoli, Giti, et al.
Publicado: (2015)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Uterine leiomyoma and its association with menstrual pattern and history of depo-medroxyprogesterone acetate injections
por: Amanti, L, et al.
Publicado: (2011)

Effects of Long-term Use of Depo-medroxyprogesterone Acetate on Lipid Metabolism in Nepalese Women
por: Yadav, Binod Kumar, et al.
Publicado: (2011)

Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem
por: Veisi, Firoozeh, et al.
Publicado: (2013)

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021)

Foreign Body Granulomas Induced by Intramuscular Leuprorelin Acetate Injection for Prostate Cancer: Clinical Mimics of Soft Tissue Sarcoma
por: Thway, Khin, et al.
Publicado: (2015)

Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
por: Saito, Seiichi
Publicado: (2019)

Formulation and Evaluation of Pharmaceutically Equivalent Parenteral Depot Suspension of Methyl Prednisolone Acetate
por: Alam, A., et al.
Publicado: (2009)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate
por: Yamauchi, Ryo, et al.
Publicado: (2020)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
por: Hapgood, Janet P.
Publicado: (2020)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
por: Kurebayashi, Junichi, et al.
Publicado: (2016)

Oxidative Stress, Lipid Profile and Liver Functions in Average Egyptian Long Term Depo Medroxy Progesterone Acetate (DMPA) Users
por: Faddah, L. M., et al.
Publicado: (2005)

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Kurebayashi, Junichi, et al.
Publicado: (2021)

Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera
por: Akinlaja, Olukayode, et al.
Publicado: (2016)

Diabetes insipidus in a patient with PCOS treated with Depo-Provera
por: Martinez, Amanda I, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bchmuqg3tv7m9184d2uc6u1oeo